Abstract
Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.
Highlights
45 De Barra E, Hodgson SH, Ewer KJ et al A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS
ChAd vaccine vectors have been shown to have a good safety & immunological profile in clinical trials ●● ChAd viral vaccines against malaria, Ebola, HIV, influenza, respiratory syncytial virus, HCV, tubercolosis and prostate cancer have all progressed to Phase I clinical trials. ●● ChAd viral vectors elicit high levels of antigen-specific T cells and/or neutralizing antibodies when administered as part of a prime boost regimen
These data together with advances in molecular engineering strategies and manufacturing technology will open up the possibility of rapidly generating Simian adenovirus (SAd) vector vaccines to combat emerging diseases, such as Ebola and Zika
Summary
Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. Vaccine vectors derived from ChAd3, 7, 6, 9, 32, 33, 63 and 68 have been generated [12] and tested in preclinical settings for immunogenicity toward a wide range of pathogens including malaria [17,18,19], HIV [20,21], influenza virus [22], Ebola [23], SARS [7], hepatitis C [24,25], rabies virus [26] and Rift Valley fever [27] These vectors have been demonstrated to induce immune responses at very low doses in mice (1–3 × 106 viral particles).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
